Express Pharma

SeQuent Scientific announces Q4FY15 and FY15 financial results

158

For Q4FY15 the operating revenue was Rs 133 crores as compared to Rs 107 crores in Q4FY14

SeQuent Scientific announced its financial results for the fourth quarter ended March 31, 2015 (Q4FY15) and full year ended March 31, 2015 (FY15). For Q4FY15 the operating revenue was Rs 133 crores as compared to Rs 107 crores in Q4FY14. Growth of 14 per cent in the continuing business. Adjusted EBITDA stood at Rs 20 crores as compared to a loss of Rs four crores during the corresponding period of previous year. The EBITDA margin was at 14.8 per cent for Q4FY15 as against -four per cent in Q4FY14. The net loss stood at Rs 19 crores for Q4FY15 as compared to a loss of Rs 80 crores in the corresponding period of the previous year.

For FY15 the operating revenue was at Rs 465 crores as compared to Rs 455 crores in FY14. The net loss stood at Rs 12 crores as compared to a loss of Rs 110 crores in FY14.

Manish Gupta, Managing Director, said, “We are pleased that we could demonstrate tangible growth and improved operating margins in the last quarter of FY15, which we believe are the result of the strategic re-alignment undertaken by the company at the beginning of the year. All our corporate actions have now been completed and this augers well for our goal to move to profitability in the coming year.”

- Advertisement -

Comments are closed.